Workflow
Supernus Announces First Quarter 2025 Financial Results

Core Insights - Supernus Pharmaceuticals reported strong financial results for Q1 2025, highlighting double-digit revenue growth from core products and adjusted operating earnings growth [2][7][12] - The company launched ONAPGO, a new treatment for Parkinson's disease, which is expected to drive further growth [2][8] Financial Performance - Q1 2025 net sales of Qelbree increased by 44% to $64.7 million compared to Q1 2024 [7] - Q1 2025 net sales of GOCOVRI increased by 16% to $30.7 million compared to Q1 2024 [7] - Total revenues for Q1 2025 increased by 4% to $149.8 million compared to Q1 2024 [7] - Adjusted operating earnings for Q1 2025 increased by 16% to $25.9 million [12] Product Pipeline - SPN-817, a novel AChE inhibitor for epilepsy, is currently in a Phase 2b study with approximately 258 patients [3] - SPN-820, aimed at treating major depressive disorder, will enter a Phase 2b trial with around 200 adults [4] - SPN-443, a novel stimulant for ADHD, completed a Phase 1 study and will announce a lead indication by the end of 2025 [5] Market and Prescription Trends - Total IQVIA prescriptions for Qelbree reached 214,908 in Q1 2025, a 22% increase year-over-year [8] - The number of prescribers for Qelbree grew to approximately 34,416 in Q1 2025, up from 27,902 in the same period last year [8] Financial Guidance - The company reiterated its full-year 2025 financial guidance, projecting total revenues between $600 million and $630 million [11] - Combined R&D and SG&A expenses are expected to be between $435 million and $460 million [11]